

500 0057

RECEIVED

Sheet 1 of 2

FORM PTO-1449 (REV 7-89)		U. S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 480124.407	APPLICATION NO. 09/696,791
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		APPLICANTS		TE OIPE JAN 29 2001	
		Joan M. Robbins and Richard Tritz		FILING DATE October 25, 2000	
		GROUP ART UNIT 1614		JAN 29 2001 PATENT & TRADEMARK OFFICE 611	

U. S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
KAL	AA	6,132,967	10/17/00	Grimm et al.	435	6	
KAL	AB	6,103,890	8/15/00	Jarvis et al.	536	245	
KAL	AC	5,929,040	7/27/99	Werther et al.	514	44	
KAL	AD	5,658,780	8/19/97	Stinchcomb et al.	295	366	
KAL	AE	5,646,042	7/8/97	Stinchcomb et al.	435	366	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

KAL	AF	Frimerman et al., "Chimeric DNA-RNA Hammerhead Ribozyme to Proliferating Cell Nuclear Antigen Reduces Stent-Induced Stenosis in a Porcine Coronary Model," <i>Circulation</i> 99:697-703, February 9, 1999
KAL	AG	LaVail et al., "Ribozyme rescue of photoreceptor cells in P23H transgenic rats: Long-term survival and late-stage therapy," <i>Proceedings National Academy Science USA</i> 97(21): 11488-11493, October 10, 2000
KAL	AH	Flores-Aguilar et al., "Evaluation of Retinal Toxicity and Efficacy of Anti-Cytomegalovirus and Anti-Herpes Simplex Virus Antiviral Phosphorothioate Oligonucleotides ISIS 2922 and ISIS 4015," <i>The Journal of Infectious Diseases</i> 175: 1308-1316, June 1997
KAL	AI	Taylor et al., "Chimeric DNA-RNA hammerhead ribozymes have enhanced <i>in vitro</i> catalytic efficiency and increased stability <i>in vivo</i> ," <i>Nucleic Acids Research</i> 20(17):4559-4565, 1992
KAL	AJ	Morita et al., "Inhibition Of Rheumatoid Synovial Fibroblast Proliferation By Antisense Oligonucleotides Targeting Proliferating Cell Nuclear Antigen Messenger RNA," <i>Arthritis Rheumatism</i> 40(7):1292-1297, July 1997
KAL	AK	Gillardon et al., "Inhibition of c-Fos expression in the UV-irradiated epidermis by topical application of antisense oligodeoxynucleotides suppresses activation of proliferating cell nuclear antigen," <i>Carcinogenesis</i> 16(8): 1853-1856, 1995

EXAMINER	Karen Diacovine	DATE CONSIDERED
		10-16-02

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV 7-80)			U. S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO 480124.407	APPLICATION NO 09/696,791
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>			APPLICANTS Joan M. Robbins and Richard Tritz			
			FILING DATE October 25, 2000	GROUP ART UNIT 1614		
U. S. PATENT DOCUMENTS						
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS
FOREIGN PATENT DOCUMENTS						
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION YES NO
OTHER PRIOR ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>						
KAL	BA	Jaskulski et al., "Inhibition of Cellular Proliferation by Antisense Oligodeoxynucleotides to PCNA Cyclin," <i>Science</i> 240: 1544-1546, June 10, 1988				
KAL	BB	Capeans et al., "A c-myc Antisense Oligonucleotide Inhibits Human Retinal Pigment Epithelial Proliferation," <i>Exp. Eye Res.</i> 66: 581-589, 1998				
KAL	BC	O'Neill et al., "Ribozyme-Based Therapeutic Approaches for Autosomal Dominant Retinitis Pigmentosa," <i>Investigative Ophthalmology & Visual Science</i> 41(10): 2863-2869, September 2000				
KAL	BD	Probst, J., "Antisense Oligodeoxynucleotide and Ribozyme Design," <i>Methods</i> 22: 271-281, 2000				
KAL	BF	Kuang-Yu Jen and Alan M. Gewirtz, "Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies," <i>Stem Cells</i> 18: 307-319, 2000				
EXAMINER	<i>Karen A. Lawrence</i>			DATE CONSIDERED	10-16-02	
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).						